Journal article

2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy

Jingmei Li, Linda S Lindstroem, Jia N Foo, Sajjad Rafiq, Marjanka K Schmidt, Paul DP Pharoah, Kyriaki Michailidou, Joe Dennis, Manjeet K Bolla, Qin Wang, Laura J Van't Veer, Sten Cornelissen, Emiel Rutgers, Melissa C Southey, Carmel Apicella, Gillian S Dite, John L Hopper, Peter A Fasching, Lothar Haeberle, Arif B Ekici Show all

Nature Communications | NATURE PUBLISHING GROUP | Published : 2014

Grants

Awarded by Swedish Research Council


Awarded by Swedish Cancer Society


Awarded by Linneus Centre


Awarded by European Community


Awarded by Cancer Research UK


Awarded by National Institutes of Health


Awarded by Post-Cancer GWAS initiative


Awarded by Department of Defence


Awarded by National Cancer Institute (USA)


Awarded by Dutch Cancer Society


Funding Acknowledgements

We thank all the individuals who took part in these studies and all the researchers, study staff, clinicians and other health care providers, technicians and administrative staff who have enabled this work to be carried out. This work was financed by the Swedish Research Council (grant number: 521-2011-3187 and 524-2011-6857 to L. L.); Gosta Miltons Donationsfond to L. L., Swedish Cancer Society (grant number: CAN 2010/807 and 5128-B07-01PAF to K. C.) and a UNESCO-L'Oreal International Fellowship to J. L. This study was also supported by the Cancer Risk Prediction Center (CRisP; www. crispcenter. org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council. Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement number 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112-the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation and the Ovarian Cancer Research Fund. The ABCFS and OFBCR work was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The OFBCR work was also supported by the Canadian Institutes of Health Research CIHR Team in Familial Risks of Breast Cancer' programme. The ABCS was funded by Dutch Cancer Society grant number NKI2007-3839; M. K. S. was funded by Dutch Cancer Society grant number NKI2009-4363. The work of the BBCC was partly funded by ELAN-Programme of the University Hospital of Erlangen. The BCAC is funded by CR-UK (C1287/A10118 and C1287/A12014). Meetings of the BCAC have been funded by the European Union COST programme (BM0606). E. S. is supported by NIHR Comprehensive Biomedical Research Centre, Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London, United Kingdom. I. T. is supported by the Oxford Biomedical Research Centre. The HEBCS was supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (132473), the Finnish Cancer Society, The Nordic Cancer Union and the Sigrid Juselius Foundation. Financial support for KARBAC was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Swedish Cancer Society, The Gustav V Jubilee foundatin and Bert von Kantzows foundation. The KBCP was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, the Academy of Finland and by the strategic funding of the University of Eastern Finland. kConFab is supported by grants from the National Breast Cancer Foundation, the NHMRC, the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. The kConFab Clinical Follow-Up Study was funded by the NHMRC, Cancer Australia and the National Breast Cancer Foundation. K. A. P. is a National Breast Cancer Foundation Practitioner Fellow. L. M. B. C. is supported by the ` Stichting tegen Kanker' (232-2008 and 196-2010). The MARIE study was supported by the Deutsche Krebshilfe e. V.(70-2892-BR I), the Hamburg Cancer Society, the German Cancer Research Center and the genotype work in part by the Federal Ministry of Education and Research (BMBF) Germany (01KH0402). MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553 and 504711, and by infrastructure provided by Cancer Council Victoria. The MEC was supported by NIH grants CA63464, CA54281, CA098758 and CA132839. The NBCS was supported by grants from the Norwegian Research council (155218/.V40, 175240/.S10 to A. L. B. D., FUGE-NFR 181600/.V11 to V. N. K. and a Swizz Bridge Award to A. L. B. D.). The OBCS was supported by research grants from the Finnish Cancer Foundation, the Sigrid Juselius Foundation, the Academy of Finland, the University of Oulu and the Oulu University Hospital. The ORIGO study was supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16). pKARMA is a combination of the KARMA and LIBRO-1 studies. KARMA was supported by Marit and Hans Rausings Initiative Against Breast Cancer. KARMA and LIBRO-1 were supported the Cancer Risk Prediction Center (CRisP; www. crispcenter. org), a Linnaeus Centre (Contract ID 70867902) financed by the Swedish Research Council. The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). SASBAC was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. K. C. was financed by the Swedish Cancer Society (5128-B0701PAF). SEARCH is funded by a programme grant from Cancer Research UK (C490/A10124) and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. SKKDKFZS is supported by the DKFZ. The TWBCS is supported by the Institute of Biomedical Sciences, Academia Sinica and the National Science Council, Taiwan. MYBRCA is funded by research grants from the Malaysian Ministry of Science, Technology and Innovation (MOSTI), Malaysian Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer Research Initiatives Foundation (CARIF). The HERPACC was supported by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sports, Culture and Technology of Japan, by a Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from Ministry Health, Labour and Welfare of Japan, by a research grant from Takeda Science Foundation, by the Health and Labour Sciences Research Grants for Research on Applying Health Technology from Ministry Health, Labour and Welfare of Japan and by the National Cancer Center Research and Development Fund. The SEBCS was supported by the Korea Health 21 R&D Project AO30001), Ministry of Health and Welfare, Republic of Korea. POSH was supported by Funding Breast Cancer Campaign (NOV210PR62) and Cancer Research UK (C1275/.A9896). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. J. L. H. is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow and M. C. S. is a NHMRC Senior Research Fellow. D. F. E. is a Principal Research Fellow of CR-UK.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.